The genetic diseases treatment startup has now raised almost $16m altogether, after closing a series A round backed by LabCorp.
Orig3n, a US-based developer of treatments for rare, inherited genetic diseases, has completed a $12.5m series A round featuring genomic testing company LabCorp.
Hatteras Venture Partners and Syno Capital co-led the round, which also included venture capital firms Defta Partners, Harris & Harris Group, MGC Venture Partners and KTB, the latter of which invested through its KTB-Korus Fund.
The series A round will fund the launch of cellular models based on the LifeCapsule bio-repository established by Orig3n earlier this year.…
